Nrf2/ARE Pathway As a Therapeutic Target for the Treatment of Parkinson Diseases

Overview

Journal Neurochem Res

Specialties Chemistry
Neurology

Date 2019 Jan 9

PMID 30617864

Citations 33

Authors

Artem P Gureev

Vasily N Popov

Affiliations

Soon will be listed here.

Abstract

Instead of the progress in the understanding of etiology of Parkinson's disease (PD), effective methods to prevent the progression of the disease have not been developed and only symptomatic treatment is currently possible. One of possible pathways to slow the progression of the disease is protection of dopaminergic neurons by maintaining mitochondrial quality control in neuron cells. Recent studies showed that the most promising target for pharmacological effects on mitochondria is the Nrf2/ARE signaling cascade. It participates in the maintenance of mitochondrial homeostasis, which is provided by an optimal ratio in the processes of mitochondrial biogenesis and mitophagy, as well as the optimal ratio of ROS production and ROS scavenging. Nrf2 activators are capable of modulating these processes, maintaining mitochondrial homeostasis in neurons. In addition, Nrf2 can synergistically interact with other transcription factors, for example, PGC-1a in the regulation of mitochondrial biogenesis and YY1 with the increase of antioxidant defense. All this makes Nrf2 an optimal target for drugs that could support the mitochondrial quality control, which, in combination with antioxidant protection, can significantly slow down the pathogenesis of PD. Some of these compounds have undergone laboratory studies and are at the stage of clinical trials now.

Citing Articles

Unraveling the role of Nrf2 in dopaminergic neurons: a review of oxidative stress and mitochondrial dysfunction in Parkinson's disease.

Kaur M, Aran K Metab Brain Dis. 2025; 40(2):123.

PMID: 39932604 DOI: 10.1007/s11011-025-01552-7.

PGC1α as a downstream effector of KDM5B promotes the progression of androgen receptor-positive and androgen receptor-negative prostate cancers.

Teramoto Y, Yang Z, Matsukawa T, Najafi M, Goto T, Miyamoto H Am J Cancer Res. 2024; 14(9):4367-4377.

PMID: 39417173 PMC: 11477833. DOI: 10.62347/QWZY6886.

Thymoquinone ameliorate oxidative stress, GABAergic neuronal depletion and memory impairment through Nrf2/ARE signaling pathway in the dentate gyrus following cypermethrin administration.

Imam A, Okesina A, Sulaimon F, Imam A, Ibiyeye R, Oyewole L BMC Neurosci. 2024; 25(1):45.

PMID: 39333878 PMC: 11428341. DOI: 10.1186/s12868-024-00896-7.

Dual role of Nrf2 signaling in hepatocellular carcinoma: promoting development, immune evasion, and therapeutic challenges.

Gan L, Wang W, Jiang J, Tian K, Liu W, Cao Z Front Immunol. 2024; 15:1429836.

PMID: 39286246 PMC: 11402828. DOI: 10.3389/fimmu.2024.1429836.

Xanthoxylin Attenuates Lipopolysaccharide-Induced Lung Injury through Modulation of Akt/HIF-1α/NF-κB and Nrf2 Pathways.

Liu F, Yang Y, Liao C, Lee H Int J Mol Sci. 2024; 25(16).

PMID: 39201430 PMC: 11354527. DOI: 10.3390/ijms25168742.

References

Wang B, Williamson G . Detection of a nuclear protein which binds specifically to the antioxidant responsive element (ARE) of the human NAD(P) H:quinone oxidoreductase gene. Biochim Biophys Acta. 1994; 1219(3):645-52. DOI: 10.1016/0167-4781(94)90223-2. View

Cherry A, Suliman H, Bartz R, Piantadosi C . Peroxisome proliferator-activated receptor γ co-activator 1-α as a critical co-activator of the murine hepatic oxidative stress response and mitochondrial biogenesis in Staphylococcus aureus sepsis. J Biol Chem. 2013; 289(1):41-52. PMC: 3879563. DOI: 10.1074/jbc.M113.512483. View

Xiao L, Xu X, Zhang F, Wang M, Xu Y, Tang D . The mitochondria-targeted antioxidant MitoQ ameliorated tubular injury mediated by mitophagy in diabetic kidney disease via Nrf2/PINK1. Redox Biol. 2016; 11:297-311. PMC: 5196243. DOI: 10.1016/j.redox.2016.12.022. View

Zhou L, Wang W, Hoppel C, Liu J, Zhu X . Parkinson's disease-associated pathogenic VPS35 mutation causes complex I deficits. Biochim Biophys Acta Mol Basis Dis. 2017; 1863(11):2791-2795. PMC: 5659972. DOI: 10.1016/j.bbadis.2017.07.032. View

Panahi Y, Khalili N, Sahebi E, Namazi S, Saberi Karimian M, Majeed M . Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial. Inflammopharmacology. 2016; 25(1):25-31. DOI: 10.1007/s10787-016-0301-4. View

Kuroda Y, Mitsui T, Kunishige M, Shono M, Akaike M, Azuma H . Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet. 2006; 15(6):883-95. DOI: 10.1093/hmg/ddl006. View

Thomas R, Keeney P, Bennett J . Impaired complex-I mitochondrial biogenesis in Parkinson disease frontal cortex. J Parkinsons Dis. 2013; 2(1):67-76. DOI: 10.3233/JPD-2012-11074. View

Whitman S, Long M, Wondrak G, Zheng H, Zhang D . Nrf2 modulates contractile and metabolic properties of skeletal muscle in streptozotocin-induced diabetic atrophy. Exp Cell Res. 2013; 319(17):2673-83. PMC: 3809009. DOI: 10.1016/j.yexcr.2013.07.015. View

Scarpulla R . Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator. Ann N Y Acad Sci. 2008; 1147:321-34. PMC: 2853241. DOI: 10.1196/annals.1427.006. View

10.

Wang Q, Li W, Dai S, Guo Y, Han F, Zheng J . Meta-Analysis of Parkinson's Disease and Alzheimer's Disease Revealed Commonly Impaired Pathways and Dysregulation of NRF2-Dependent Genes. J Alzheimers Dis. 2017; 56(4):1525-1539. DOI: 10.3233/JAD-161032. View

11.

Ascherio A, LeWitt P, Xu K, Eberly S, Watts A, Matson W . Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009; 66(12):1460-8. PMC: 2795011. DOI: 10.1001/archneurol.2009.247. View

12.

Puschmann A . Monogenic Parkinson's disease and parkinsonism: clinical phenotypes and frequencies of known mutations. Parkinsonism Relat Disord. 2013; 19(4):407-15. DOI: 10.1016/j.parkreldis.2013.01.020. View

13.

Prestera T, Talalay P, Alam J, Ahn Y, Lee P, Choi A . Parallel induction of heme oxygenase-1 and chemoprotective phase 2 enzymes by electrophiles and antioxidants: regulation by upstream antioxidant-responsive elements (ARE). Mol Med. 1995; 1(7):827-37. PMC: 2230011. View

14.

Whiteman M, Ketsawatsakul U, Halliwell B . A reassessment of the peroxynitrite scavenging activity of uric acid. Ann N Y Acad Sci. 2002; 962:242-59. DOI: 10.1111/j.1749-6632.2002.tb04072.x. View

15.

Zenkov N, Menshchikova E, Tkachev V . Keap1/Nrf2/ARE redox-sensitive signaling system as a pharmacological target. Biochemistry (Mosc). 2013; 78(1):19-36. DOI: 10.1134/S0006297913010033. View

16.

Salat D, Tolosa E . Levodopa in the treatment of Parkinson's disease: current status and new developments. J Parkinsons Dis. 2013; 3(3):255-69. DOI: 10.3233/JPD-130186. View

17.

Sun J, Ren X, Simpkins J . Sequential Upregulation of Superoxide Dismutase 2 and Heme Oxygenase 1 by tert-Butylhydroquinone Protects Mitochondria during Oxidative Stress. Mol Pharmacol. 2015; 88(3):437-49. PMC: 4551047. DOI: 10.1124/mol.115.098269. View

18.

Ahuja M, Kaidery N, Yang L, Calingasan N, Smirnova N, Gaisin A . Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease. J Neurosci. 2016; 36(23):6332-51. PMC: 4899530. DOI: 10.1523/JNEUROSCI.0426-16.2016. View

19.

Aguiar Jr A, Duzzioni M, Remor A, Tristao F, Matheus F, Raisman-Vozari R . Moderate-Intensity Physical Exercise Protects Against Experimental 6-Hydroxydopamine-Induced Hemiparkinsonism Through Nrf2-Antioxidant Response Element Pathway. Neurochem Res. 2015; 41(1-2):64-72. DOI: 10.1007/s11064-015-1709-8. View

20.

Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V . Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 1999; 98(1):115-24. DOI: 10.1016/S0092-8674(00)80611-X. View